Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications
- PMID: 22015612
- PMCID: PMC11115117
- DOI: 10.1007/s00018-011-0856-6
Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications
Abstract
Nanoparticles (NPs) comprised of nanoengineered complexes are providing new opportunities for enabling targeted delivery of a range of therapeutics and combinations. A range of functionalities can be included within a nanoparticle complex, including surface chemistry that allows attachment of cell-specific ligands for targeted delivery, surface coatings to increase circulation times for enhanced bioavailability, specific materials on the surface or in the nanoparticle core that enable storage of a therapeutic cargo until the target site is reached, and materials sensitive to local or remote actuation cues that allow controlled delivery of therapeutics to the target cells. However, despite the potential benefits of NPs as smart drug delivery and diagnostic systems, much research is still required to evaluate potential toxicity issues related to the chemical properties of NP materials, as well as their size and shape. The need to validate each NP for safety and efficacy with each therapeutic compound or combination of therapeutics is an enormous challenge, which forces industry to focus mainly on those nanoparticle materials where data on safety and efficacy already exists, i.e., predominantly polymer NPs. However, the enhanced functionality affordable by inclusion of metallic materials as part of nanoengineered particles provides a wealth of new opportunity for innovation and new, more effective, and safer therapeutics for applications such as cancer and cardiovascular diseases, which require selective targeting of the therapeutic to maximize effectiveness while avoiding adverse effects on non-target tissues.
Figures

Similar articles
-
Nanocarriers for tracking and treating diseases.Curr Med Chem. 2013;20(28):3500-14. doi: 10.2174/0929867311320280007. Curr Med Chem. 2013. PMID: 23834187 Free PMC article. Review.
-
Theranostic Nanoparticles for RNA-Based Cancer Treatment.Acc Chem Res. 2019 Jun 18;52(6):1496-1506. doi: 10.1021/acs.accounts.9b00101. Epub 2019 May 28. Acc Chem Res. 2019. PMID: 31135134 Free PMC article. Review.
-
Protein nanoparticles as drug delivery carriers for cancer therapy.Biomed Res Int. 2014;2014:180549. doi: 10.1155/2014/180549. Epub 2014 Mar 20. Biomed Res Int. 2014. PMID: 24772414 Free PMC article. Review.
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
-
Polymeric nanoparticles as carrier for targeted and controlled delivery of anticancer agents.Ther Deliv. 2019 Aug;10(8):527-550. doi: 10.4155/tde-2019-0044. Epub 2019 Sep 9. Ther Deliv. 2019. PMID: 31496433 Review.
Cited by
-
Formulation and Characterization of Phytostanol Ester Solid Lipid Nanoparticles for the Management of Hypercholesterolemia: An ex vivo Study.Int J Nanomedicine. 2021 Mar 9;16:1977-1992. doi: 10.2147/IJN.S276301. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33727810 Free PMC article.
-
Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair.Pharmacol Res. 2017 Nov;125(Pt B):232-245. doi: 10.1016/j.phrs.2017.08.013. Epub 2017 Sep 22. Pharmacol Res. 2017. PMID: 28855094 Free PMC article. Review.
-
A comprehensive review of using nanomaterials in cancer immunotherapy: Pros and Cons of clinical usage.3 Biotech. 2025 Jul;15(7):205. doi: 10.1007/s13205-025-04362-x. Epub 2025 Jun 9. 3 Biotech. 2025. PMID: 40502964 Review.
-
The Effects of Fibrin-icariin Nanoparticle Loaded in Poly (lactic-co-glycolic) Acid Scaffold as a Localized Delivery System on Chondrogenesis of Human Adipose-derived Stem Cells.Adv Biomed Res. 2020 Feb 25;9:6. doi: 10.4103/abr.abr_143_19. eCollection 2020. Adv Biomed Res. 2020. PMID: 32181230 Free PMC article.
-
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer.Int J Mol Epidemiol Genet. 2011;2(4):367-90. Epub 2011 Nov 25. Int J Mol Epidemiol Genet. 2011. PMID: 22199999 Free PMC article.
References
-
- Loomis K, McNeeley K, Bellamkonda RV. Nanoparticles with targeting, triggered release, and imaging functionality for cancer applications. Soft Matter. 2011;7(3):839–856. doi: 10.1039/c0sm00534g. - DOI
-
- Su X, Zhan X, Tang F, Yao JY, Wu J. Magnetic nanoparticles in brain disease diagnosis and targeting drug delivery. Curr Nanosci. 2011;7(1):37–46. doi: 10.2174/157341311794480363. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous